Comment by notlob

I see where you're coming from now. ABX (antibiotics) are a bit unique. New ABX are sparingly profitable because they are usually incremental developments instead of new classes of compounds. A new class would be lucrative. I see this as a reflection that ABX dev is a ridiculously hard problem with many failures. There are many working in this area, but not much to show yet.